Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pediarix TM, Infanrix penta TM · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Single Group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Pediarix TM, Infanrix penta TM | BIOLOGICAL | The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age. |
| Hiberix TM | BIOLOGICAL | The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age. |
Inclusion Criteria: * A male or female infant between 6 and 8 weeks of age at the time of the first vaccination. * Free of obvious health problems as established by medical history and clinical examination before entering into the study. * Written informed consent obtained from the parents or guard...
Pediarix TM, Infanrix penta TM is a combination vaccine used for immunization against diphtheria, poliomyelitis, hepatitis B, tetanus, and acellular pertussis in infants. It is being developed by GSK plc for the prevention of these infectious diseases.
Pediarix TM, Infanrix penta TM is developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The vaccine is intended for use in infants to protect against multiple infectious diseases.
Pediarix TM, Infanrix penta TM is in Phase 3 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the vaccine remains under clinical investigation.
Pediarix TM, Infanrix penta TM has one completed Phase 3 clinical trial, identified as NCT00879827. This trial evaluated the immunogenicity and reactogenicity of the vaccine when coadministered to healthy infants aged 6 weeks and older.
Yes, Pediarix TM and Infanrix penta TM are alternative names for the same vaccine product developed by GSK plc. The vaccine is designed to protect against diphtheria, poliomyelitis, hepatitis B, tetanus, and acellular pertussis.